2 Prague European Days of Internal Medicinefiles.test-pedim.webnode.cz/200000398-593275a2d8/... · Hotel Diplomat, Prague, Czech Republic 4 2 Prague European 5 Days of Internal Medicine

FINAL PROGRAMME

2nd Prague European Days of Internal MedicineDecember 1–2, 2016Hotel DiplomatPrague, Czech Republic

2nd Prague European Days of Internal MedicineDecember 1–2, 2016Hotel Diplomat, Prague, Czech Republic

32 2nd Prague European Days of Internal Medicine

December 1–2, 2016Hotel Diplomat, Prague, Czech Republic

CONTENTWELCOME LETTER 4

GENERAL INFORMATION 6

CONFERENCE SECRETARIAT 6

CONFERENCE VENUE 7

REGISTRATION 7

INFORMATION FOR PARTICIPANTS 8

INFORMATION FOR SPEAKERS 9

INFORMATION FOR POSTER PRESENTATION 9

CONFERENCE VENUE FLOORPLAN 10

PROGRAMME AT A GLANCE 11

SCIENTIFIC PROGRAMME

THURSDAY, DECEMBER 1, 2016 12

FRIDAY, DECEMBER 2, 2016 15

LIST OF POSTERS 20

GENERAL INFORMATION 23

INDUSTRY SUPPORTED SYMPOSIA 24

PARTNERS 31




WELCOME LETTERDear Colleagues and Friends,

Please allow me to cordially welcome you to Prague on behalf of the Organizing Committee of the 2nd Prague European Days of Internal Medicine (PEDIM) Conference. This is my pleasure and honor to inform you, that our meeting is endorsed by the European Federation of Internal Medicine (EFIM) as an official event.

I assure you that we have done our utmost to ensure that your conference is both enlightening and enjoyable. That having been said, it is veritably impossible to organize such an event without encountering a few minor issues along the way. Should any arise, I do hope you will find it possible to overlook them in light of our beautiful “City of a Hundred Spires.“ Prague has a very special atmosphere, which developed out of history, tradition, art, architecture, culture and a sense for the finer things in life. I trust that you will avail yourselves of this opportunity to experience the unique ambience of our city, this year, in addition, in the atmosphere of coming Christmas, in Advent.

First and foremost, however, we have convened to deliberate matters pertaining to internal medicine, the very cornerstone of complex, integrated medical care. The objective of this conference is to improve the current state of health care in our countries. At present, it is characterized by an ageing population; metabolic, cardiovascular and other noninfectious disease epidemics. However, new possibilities of treatment are becoming available, and it is our great advantage, that we will have a chance to discuss such a treatment with many opinion leaders. This year, we are focusing on metabolic disorders and cardiology, taking in count the great impact of cardiometabolic risk. However, other disciplines are not omitted as well. General internal medicine is than apparent in all presentations.

In addition, the tremendous scientific benefits of plenary lectures, case reports, posters and other presentations will be invaluable.

I would also like to express my thanks and appreciation to the medical opinion leaders who graciously accepted our invitation to join the international organizing committee and advisory board. Also, it is my duty to express our thanks to sponsors and partners. Without their help and participation it would be almost impossible to organize such a meeting.

A couple years ago, some believed internal medicine to be a dying field; one that had already been superseded by other branches of medicine. This is no longer the case: Internal medicine is not dying.

Just as the mythical phoenix rose from its own ashes, so too has internal medicine and I firmly believe that the 2nd PEDIM will provide more than sufficient evidence to confirm the continuing importance of our discipline.

I wish all of you a wonderful stay in Prague and I sincerely hope that PEDIM will prove to be an interesting, productive and unforgettable event for all of us.

Richard Ceska, MD, PhD, FACP, FEFIMProfessor of Internal MedicinePresident of the Czech Society of Internal MedicineConference President, PEDIM 2016




GENERAL INFORMATIONHosted by

In Cooperation with

Endorsed by

Conference PresidentRichard Ceska, MD, PhD, FACP, FEFIMProfessor of Internal Medicine

Chair of the Scientific CommitteeJiri Widimsky jr., MD, PhDProfessor of Internal Medicine

CONFERENCE SECRETARIATGUARANT InternationalNa Pankraci 17, 140 21 Prague 4Czech RepublicPhone: +420 284 001 444Fax: +420 284 001 448E-mail: [email protected]

CONFERENCE VENUEConference Prague European Days of Internal Medicine is being held at the Diplomat Hotel which is located near the city center. It is easily accessible by both public and private transport.

Diplomat Hotel PragueEvropská 15, 160 41 Prague 6Czech RepublicPhone: +420 296 559 111www.diplomathotel-prague.com

REGISTRATIONRegistration Fees

ON-SITE FEEDelegates 480 EURYoung Internists (up to 35 years)* 380 EUR

*ID to be presentedRegistration fees include 21 % VAT.

The Registration Fee Includes:• Attending all Conference Scientific Sessions• Admission to the Exhibition Area and Poster Session• Conference materials• Coffee breaks• Lunch box

Registration Opening HoursWednesday, November 30, 2016 17:00–20:00Thursday, December 1, 2016 07:45–18:00Friday, December 2, 2016: 08:00–17:30

mailto:[email protected]

http://www.diplomathotel-prague.com




INFORMATION FOR PARTICIPANTSCME AccreditationWe are pleased to inform you that 2nd Prague European Days of Internal Medicine was granted 10 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

2nd Prague European Days of Internal Medicine is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

2nd Prague European Days of Internal Medicine is designated for a maximum of 10 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Certificate of AttendanceCME certificates are to be handed out to participants at the Registration Desk. Certificates are to be handed out only based on completed feedback form.

Name BadgeParticipants receive a name badge. Everyone is requested to wear this badge for all conference activities. In case of loss, a new name badge can be printed for a fee of 30 EUR.

LanguageThe official language of the conference is English. Translation is not provided.

INFORMATION FOR SPEAKERSPlease come to the Speakers’ Ready Room (Meeting room Paris) at least 2 hours before the beginning of your session. In case your speech has been scheduled for morning session please come to the Speakers’ Ready Room one day before the day of your presentation.

Speakers’ Ready Room Opening HoursWednesday, November 30, 2016 17:00–20:00Thursday, December 1, 2016 07:45–18:00Friday, December 2, 2016 08:00–17:00

INFORMATION FOR POSTER PRESENTATION Poster mounting timesThursday, December 1, 2016 07:45–10:00

Poster viewingThursday, December 1, 2016 10:00–17:45Friday, December 2, 2016 08:30–17:30

Poster removal times*Friday, December 2, 2016 17:30–18:00

*All remaining posters after removal times will be removed and the will not be kept for later collection.

Book of AbstractsBook of Abstracts is available online at the conference website www.pedim2016.org

http://www.uems.net

http://www.ama-assn.org/go/internationalcme

http://www.pedim2016.org




CONFERENCE VENUE FLOORPLAN PROGRAMME AT A GLANCEThursday, December 1, 2016

PRAGUE Room (A-B-C) PRAGUE Room (D) 08:45-09:00 Opening ceremony09:00–10:30 Metabolic syndrome and epidemiology10:30–11:30 Heart failure11:30–12:00 Coffee break

12:00–12:30 Industry sponsored symposium

(see page 24)12:15–13:00

Young internists12:30–13:00 Lunch break Lunch break

13:00–14:30How to implement the knowledge

of CVD risk in patients with RA into clinical practice

14:30–15:30 Nephrology 15:00–17:00ScreenPro FH Symposium(focused on modern lipid

lowering combo therapy, familial hypercholesterolemia, statin

intolerance and metabolic syndrome)

15:30–15:45 Coffee break 15:45–16:45 Fixed combination in internal medicine

16:45–17:45 Top stories in internal medicine

Friday, December 2, 2016PRAGUE Room (A-B-C) PRAGUE Room (D)

09:00–10:00 HypertensionFree communication – Varia,

Intensive care, Rheumatology and CVD

10:00–11:00 Stroke: A challenge for internal

medicineFree communication –

General internal medicine11:00–11:30 Coffee break Coffee break

11:30–12:30Industry sponsored symposium

(see page 24)12:30–13:00 Lunch break Lunch break13:00–14:00 Diabetes Free communication – Hypertension

14:00–15:00 Clinical lipidologyFree communication –

Metabolic syndrome15:00–15:15 Coffee break Coffee break

15:15–16:15 General internal medicineFree communication – Atherosclerosis,

Heart failure, Hyperlipidemia and dyslipidemia, Stroke

16:15–17:15 Intensive care in internal medicine17:15–17:30 Closing ceremony

PRAGUERoom

(A-B-C)

PRAGUERoom

(D)

Registration

Poster Area

Cloakroom

Speakers’ReadyRoom

OrganizingCommittee

Exhibition and Coffee Breaks




13:00–14:30 How to implement the knowledge of CVD risk in patients with RA into clinical practice

Chair: A. G. Semb (Norway) Cardiovascular risk evaluation and CVD in patients with RA A. G. Semb (Norway) Management of CV risk and disease in RA S. Rollefstad (Norway) Guidelines for CVD prevention in inflammatory joint diseases T. R. Pedersen (Norway)

14:30–15:30 Nephrology Chair: V. Tesař (Czech Republic)

EMPA_REG Outcome and other antidiabetic drugs – the view of nephrologist V. Tesař (Czech Republic), Ch. Wanner (Germany) NOACs in patients with renal impairment J. Vachek (Czech Republic)

15:30–15:45 Coffee break

15:45–16:45 Fixed combination in internal medicine Chairs: M. Banach (Poland), J. Widimský jr. (Czech Republic)

Fixed combination: A modern approach for better compliance in lipid disorders patients

M. Banach (Poland) Fixed combination in hypertension: Gold standard in the treatment J. Widimský jr. (Czech Republic)

16:45–17:45 Top stories in internal medicine Chair: V. Kokorin (Russia)

Top stories in internal medicine J. Václavík (Czech Republic) Polypill: Pros and cons M. Mamedov (Russia) Acute coronary syndromes and diabetes mellitus: links and feature V. Kokorin (Russia)

SCIENTIFIC PROGRAMME

THURSDAY, DECEMBER 1, 2016PRAGUE room (A-B-C)

08:45–09:00 Opening ceremony R. Češka (Czech Republic), J. Widimský jr. (Czech Republic)

09:00–10:30 Metabolic syndrome and epidemiology Chair: R. Cífkova (Czech Republic)

Metabolic surgery effects and post bariatric treatment D. Dicker (Israel) The decrease in CHD mortality in the Czech Republic and its causes R. Cífkova (Czech Republic) Prospective study of Slovak forty-year old population – cardiovascular

mortality and morbidity after ten years of follow-up. K. Rašlová (Slovakia) Physical activity in the prevention of cardiovascular disease:

is there a J curve? D. Lović (Serbia)

10:30–11:30 Heart failure Chair: J. Murín (Slovakia)

Heart failure – the task for internist. Current pharmacological treatment. J. Murín (Slovakia) Complex approach to the treatment of acute heart failure J. Bělohlávek (Czech Republic)


12:00–12:30 Industry sponsored symposium (see page 24)

12:30–13:00 Lunch break




FRIDAY, DECEMBER 2, 2016PRAGUE room (A-B-C)

09:00–10:00 Hypertension Chair: J. Widimský jr. (Czech Republic)

Fibromuscular dysplasia in clinical practice: Current experience from the European network.

A. Persu (Belgium) Non-pharmacological approach to the therapy of severe hypertension J. Widimský jr. (Czech Republic)

10:00 – 11:00 Stroke: A challenge for internal medicine Chair: M. Táborský (Czech Republic)

Endovascular therapy of acute ischemic stroke P. Widimský (Czech Republic) Prevention of stroke: Current options for risk factors management M. Vrablík (Czech Republic) Atrial fibrillation and stroke M. Táborský (Czech Republic)


11:30–12:30 Industry sponsored symposium (see page 24)

12:30–13:00 Lunch break

13:00–14:00 Diabetes Chair: P. Nilsson (Sweden)

13:00–13:25 Drug treatment of type 2 diabetes P. Nilsson (Sweden)13:25–13:50 Complications of type 2 diabetes J. Škrha jr. (Czech Republic)13:50–14:00 Lipid modification in type 1 diabetic patients S. Savla (United Kingdom)

PRAGUE room (D)

12:15–13:00 Young internists Chairs: J. Škrha jr. (Czech Republic), J. Václavík (Czech Republic)

Challenging clinical case J. Václavík (Czech Republic) European education in internal medicine. Recommendation from UEMS. J. Škrha jr. (Czech Republic) Potential use of circulating microRNAs in the clinical practice J. Novák (Czech Republic)

15:00–17:00 ScreenPro FH Symposium New Therapies for Hyperlipidemias in Clinical Practise Focused on FH and other genetically determined HLPs

15:00–15:15 Familial hypercholesterolemia – an overview (diagnosis and screening) R. Češka (Czech Republic)15:15–15:30 Statin intolerance M. Banach (Poland)


15:45–16:00 Severe FH T. Freiberger (Czech Republic) 16:00–16:15 Lp(a) M. Ezhov (Russia) 16:15–17:00 Reports from selected countries




PRAGUE room (D)

09:00–10:00 Free Communication – Varia, Intensive care, Rheumatology and CVD Chairs: E. Belousova (Russia), O. Boeva (Russia)

Varia Digestive tract pathology of patients with gout M. Petrova (Russia)

Intensive care Score in gout patients in Yakutsk M. Petrova (Russia)

Rheumatology and CVD Frequency of Inflammatory Back Pain and Structural Changes of Axial

Skeleton in Inflammatory Bowel Disease E. Belousova (Russia) Clinical Predictors of Outcomes in Calcific Aortic Valve Disease O. Boeva (Russia)

10:00–11:00 Free Communication – General internal medicine Chairs: J. Galuszka (Czech Republic), J. Magallanes Gamboa (Spain)

Adverse effects of spironolactone during long-term treatment of resistant arterial hypertension

J. Václavík (Czech Republic) Sensitivity and specificity of fecal NGAL in the management of Crohn’s

disease patients D. Abdulganieva (Russia) Mitral valve prolapse – the results of 15 years observation O. Nikolin (Russia) Hydration Matters – A Quality Improvement Project for Improving Intravenous

fluid prescribing practices and documentation in line with NICE CG174 guidance O. Husain (United Kingdom) Plasma lipidomic profiling in patients with cardiac arrhythmias J. Galuszka (Czech Republic) Determinant factors of the mortality for pneumonia in a service

of Internal Medicine J. Magallanes Gamboa (Spain)


14:00–15:00 Clinical lipidology Chair: T. Pedersen (Norway)

Lipid lowering in the light of clinical trials T. Pedersen (Norway) Current treatment with lipid lowering drugs R. Češka (Czech Republic) Recent treatment of familial chylomicronemia T. Štulc (Czech Republic)


15:15–16:15 General internal medicine Chairs: M. Durusu Tanriover (Turkey), R. Češka (Czech Republic)

15:15–15:40 Adult vaccination in Europe M. Durusu Tanriover (Turkey)15:40–16:05 Compliance: The new problem of internal medicine R. Češka (Czech Republic)16:05–16:15 Thrombotic thrombocytopenic purpura and Hodgkin’s lymphoma –

an unlikely connection C. F. G. Canelas (Portugal)

16:15–17:15 Intensive care in internal medicine Chair: K. Cvachovec (Czech Republic)

Intensive care in internal medicine. The view of anesthesiologist. K. Cvachovec (Czech Republic) Hypertensive crisis treatment T. Janota (Czech Republic)

17:15–17:30 Closing ceremony R. Češka (Czech Republic), J. Widimský jr. (Czech Republic)




15:15–16:15 Free Communication – Atherosclerosis, Heart failure, Hyperlipidemia and dyslipidemia, Stroke

Chairs: J. Hubáček (Czech Republic), G. Dori (Israel)

Atherosclerosis Analysis of risk factors and characteristics of genetic predisposition

and clinical–angiographic manifestations of atherosclerosis in patient with ischemic organ damage without stenotic vascular damage

H. Shabalina (Russian Federation) Atherosclerosis and Chronic Kidney Disease E. Moubarak (Lebanon) Internist’s view on the problem of cardiovascular patient’s preparation

for operations A. Artemova (Russia)

Heart failure Left ventricular end systolic and diastolic volumes and ejection fraction

in patients with heart failure and preserved ejection fraction – meta-analysis, graphic presentation and their relation with concentric hypertrophy

G. Dori (Israel)

Hyperlipidemia and dyslipidemia Common polymorphisms as strong predictors of hypertriglyceridemia

in Czech population J. Hubáček (Czech Republic)

Stroke Amidolytic activity of haemostasis factors activated from zymogens

in plasma under influence of stroke peptide pool T. Katrii (Ukraine)

13:00–14:00 Free Communication – Hypertension Chairs: V. Gafarov (Russia), B. Štrauch (Czech Republic)

Can the addition of statins to antihypertensive monotherapy replace combination treatment in some hypertensive patients?

D. Nebieridze (Russia) Gender features in risk of hypertension in population with depression

in Russia/Siberia: WHO epidemiological program MONICA-psychosocial V. Gafarov (Russia) Home BP telemonitoring system with data transmitted to a physician’s office J. Mužík (Czech Republic) Influence of metabolic syndrome on course of arterial hypertension

with the position of evaluation the central aortic pressure and arterial stiffness L. Andreeva (Russia) Patient’s noncompliance with the antihypertensive treatment – a frequent

cause of resistant hypertension B. Štrauch (Czech Republic) Descriptive study to evaluate patients with chest pain admitting

to Preliminary Care Unit (PCU) D G H Ampara, Sri Lanka N. Hettiarachchi (Sri Lanka)

14:00–15:00 Free Communication – Metabolic syndrome Chairs: M. Szántová (Slovakia), N. Hettiarachchi (Sri Lanka)

The frequency of the main factors of risk for CHD in women in different age groups F. Gasimova (Azerbaijan) Epidemiologic survey of lifestyle factors in Slovak outpatients M. Szántová (Slovakia) A community based study to assess the prevalence of Non Communicable

Diseases and their risk factors among rural population of Sri Lanka S. Manilgama (Sri Lanka) Descriptive study to evaluate the risk of Metabolic Syndrome among health

staff members at District General Hospital Ampara, Sri Lanka N. Hettiarachchi (Sri Lanka) A community based study to assess the awareness of Non-Communicable

Diseases among rural population of Sri Lanka S. Manilgama (Sri Lanka)





P-16 Rhabdomyolysis and Wernicke-Korsakoff Syndrome – a clinical case J. Andrade, J. Barradas, V. Romão, A. Lemos, A. MonteiroP-17 Secondary failure of etanercept therapy in case of good drug level and anti-drug

antibodies absence R. Međedović, E. Strujić, A. Međedović, N. Miketić, D. Pravilović LutovacP-18 Spontaneous coronary artery dissection I. SimkovaP-19 Tuberculosis during infliximab therapy – latent infection activation or unwanted

therapy consequence? R. Međedović, E. Strujić, A. Međedović, N. Miketić, D. Pravilović LutovacP-20 Unrecognized and untreated chronic hypoxia – case report E. Strujić, Z. Vukčević

Heart failureP-21 Psychoemotional changes at chronic heart failure S. A. Matskevich, O. A. Barbuk, M. I. BelskayaP-22 The study of neurohumoral factors in patients with chronic heart failure N. A. Nuritdinov, D. D. K. Avezov

Hyperlipidemia and dyslipidemiaP-23 Associations between equivalent radiation dose and blood lipids A. S. Kerimkulova, A. M. Markabayeva, L. M. Pivina, A. S. OspanovaP-24 Generalized Lipodystrophy as a Rare Cause of Heart Failure I. Refatllari, A. Banushi, S. Husi, F. Toti, A. GodaP-25 The analysis of HDL-cholesterol quantity among middle aged Lithuanian adults S. Kutkienė, Ž. Petrulionienė, A. Laucevičius, J. Staigytė, A. Šaulytė, E. Rinkūniene,

V. DženkevičiūtėP-26 The dynamics of serum lipid profile among middle aged Lithuanian adults

with dyslipidemia from 2009 to 2015 S. Kutkienė, Ž. Petrulionienė, A. Laucevičius, J. Staigytė, A. Šaulytė, E. Rinkūnienė,

V. Dženkevičiūtė

HypertensionP-27 Assessment of factors for adherence to treatment in hypertensive patients L. B. Dyussenova, L. M. Pivina, A. S. Kerimkulova, T. I. BelickinaP-28 Blood pressure components and lipids: acquainted traits of cardiovascular disease

development E. V. Pello, T. V. Kouznetsova, Y. P. Nikitin, J. A. StaessenP-29 Mortality rates by ethnicity among patients suffering from hypertension A. S. Kerimkulova, V. R. Veber, L. G. Proshina, M. P. Rubanova

Intensive careP-30 Ethical aspects of enrolling cardiac arrest victims into a research project T. Sudová, J. Bělohlávek, M. Zvěřová

LIST OF POSTERSAtherosclerosisP-01 Serum chemerin and fibroblast growth factor-21 levels in acquired aorta valve

stenosis patients J. Lurins, A. Visocka, G. Krievina, V. Mackevics, P. Tretjakovs

DiabetesP-02 Can a diabetes affect atherosclerosis? D. Gabrielyan, L. Gabrielyan, M. IvanovP-03 Gliflozin as a possible cause of severe metabolic disorder – case report M. Protuš, J. Kopecký, E. Uchytilová, P. WohlP-04 Lipid disorders in patients with diabetic foot – efficacy of therapy and relation

to amputation and mortality A. Nemcova, A. Jirkovska, M. Dubsky, R. Bem, V. Fejfarova, V. Woskova, A. Pysna, J. SkibovaP-05 Lipid modification in type 1 diabetic patients S. SavlaP-06 Prevalence of diabetic neuropathy among patients with type 2 diabetes mellitus Z. S. Akbarov, G. A. Khaidarova, N. N. Maksutova, F. A. TakhirovaP-07 The impact of inherited thrombophilia on the effect of cell therapy of critical limb

ischemia in diabetic patients M. Dubsky, A. Jirkovska, L. Pagacova, R. Bem, A. Nemcova, V. Fejfarova, A. Pysna, K. Navratil

General internal medicineP-08 A Retrospective Study on Poisoning Deaths in District General Hospital (DGH) Ampara,

Sri Lanka N. M. Hettiarachchi, S. R. Manilgama, R. Sampath, N. Munaweera, S. KumaraP-09 A Review of Fixed Drug Eruption due to Fluconazole B. Mistry, J. BeeckerP-10 Cardiac complications in patients who underwent radical cystectomy M. R. Atabegashvili, D. P. KotovaP-11 Changes in the levels of cytokines in course of autoimmune hepatitis D. R. Akberova, D. I. Abdulganieva, A. K. Odintsova, E. MartynovaP-12 Co-existent Miliary Tuberculosis and Non-Hodgkin’s Lymphoma – A Case Report A. Ah-Moye, I. Ferreira, S. SasikumarP-13 Have electronic drug charts made prescribing intravenous fluids more dangerous?

A quality improvement project improving the safety of intravenous prescription and administration using an electronic system

M. Geddes-Barton, K. Florman, D. AlexanderP-14 Pericardial Effusion: A Cause Beyond the Obvious G. Vasconcelos, C. Couto, T. Esteves Rodrigues, P. Matos, L. Torres, A. Castro, M. MesquitaP-15 Psoriasis – unwanted consequence of anti TNF alpha therapy E. Strujić, S. Aligrudić, D. Pravilović Lutovac




Metabolic syndromeP-31 Antihypertensive therapy using two free dosed combination of drugs with calcium

channel blocker and angiotensin receptor blocker in patients with metabolic syndrome A. Alyavi, B. Alyavi, J. UzokovP-32 Correction of infectious-inflammatory process in experimental burn disease of stage

septic toxaemia N. M. ChornenkaP-33 The Metabolic syndrome and Lipids E. Janeková, J. Babjaková, Ľ. Argalášová

NephrologyP-34 Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients-single center

experience Z. Dimitrijevic, P. Vesovic, B. Mitic, M. Vucic

Rheumatology and CVDP-35 Cardiac Involvement in Systemic Sclerosis M. Lezha, Erv. Rapushi, A. BanushiP-36 Cryoglobulinemic vasculitis in a Systemic Lupus Erythematosus patient Erv. Rapushi, V. Salko, A. Zoto, T. Backa, D. Ruci, L. Nuhaj, A. Perolla, A. Doko, I. Refatllari,

Eri. RapushiP-37 Electrophysiological remodeling of the heart in patients with ankylosing spondylitis L. I. Feiskhanova, A. A. Nigmatyanova, E. Gutieva

StrokeP-38 Secondary Prevention Following Acute Ischaemic Stroke or Transient Ischaemic Attack

(TIA) in Hospital A. Ah-Moye, S. Y. Lee

VariaP-39 A Doctor’s Dilemma Solved by the Patient E. Hasani, I. Refatllari, R. Hasani, A. BanushiP-40 Analysis of drug induced liver injury at internal department M. Szantova, Z. Durkovicova, J. SedlackoP-41 Experimental model of an acid esophagus burn and its main clinical biochemical parameters T. V. Koval, T. V. Ishchuk, Y. B. Raetska, O. M. SavchukP-42 Chromosome 15 breakage: A strongly possible cause of both ostium secundum atrial

septal defect and acute promyelocytic leukemia in a 22 years old female A. Perolla, A. Banushi, A. Demiraj, A. BabametoP-43 Role of mycobacterium tuberculosis MPT63 and MPT83 antigens in mechanisms

of immune cells activation in vitro A. Siromolot, O. Oliinyk, D. Kolibo P-44 The impact of CYP4F2 G1347A genotype on patients` plasma metabolic activity after

stent implantation V. Zvikas, V. Tatarunas, V. Skipskis, V. Jakstas, V. Lesauskaite

GENERAL INFORMATIONPublic TransportPrague has a very sophisticated public transport system. The Prague metro is quite new and efficient. At peak times, trains run every 2 or 3 minutes, and during off-peak hours at least every 8 minutes.

Taxi ServiceIn the city centre, taxis are easy to take from the street but we strongly recommend you use hotel taxis or to call a taxi by phone through the radio taxi service.

We recommend you use following taxi companies:AAA Taxi: +420 14 0 14Profi Taxi: +420 14 0 15

InsuranceThe organisers do not accept responsibility for individual medical, travel or personal insurance. All participants are strongly advised to take out their own personal insurance before travelling to the conference.

Currency & BankingCzech crown (CZK) is the official currency of the Czech Republic. Exchange of foreign currency is available at Prague international Airport and at most hotels, banks and exchange offi ces throughout the city. International credit cards are accepted for payments in hotels, restaurants and shops. Payment in cash in EUR is also available in some restaurants and shops, please ask for details on-site. You can fi nd the official exchange rates on the website of the Czech National Bank at www.cnb.cz.

ShoppingMost shops in Prague are open from 9:00 to 18:00, Monday to Saturday. Shops in the city centre are usually open from 9:00 to 21:00, Monday to Sunday.

Useful telephone numbers112 – General Emergency for Europe150 – Fire 155 – Ambulance156 – Prague Municipal Police158 – Police



SACZ1650282 Praluent Ad EN_148x210 v03 press.indd 1 21.11.16 16:25

INDUSTRY SUPPORTED SYMPOSIA

THURSDAY, DECEMBER 1, 2016PRAGUE room (A-B-C)

12:00–12:30 MSD symposium Primary prevention of HPV-related diseases T. Fait (Czech Republic)

FRIDAY, DECEMBER 2, 2016PRAGUE room (A-B-C)

11:30–12:30 Sanofi symposium Management of hyperlipidemia in patients with high / very high cardiovascular

risk: role of alirocumab in clinical practice Chair: R. Češka (Czech Republic)

Welcome and introduction R. Češka (Czech Republic) Patient with familial hypercholesterolemia M. Vrablík (Czech Republic) Patient with acute coronary syndrome and hypercholesterolemia J. Murín (Slovakia) Diabetic patient with mixed dislipidemia M. Haluzík (Czech Republic)

Česká tradiceod roku 1883

130 let ve službách zdraví

Česká tradiceod roku 1883

130 let ve službách zdraví

jako ignorovat jeho vysoký LDL-cholesterol!

Reference: 1. SPC Zoletorv.Zkrácená informace o léčivém přípravkuZoletorv® 10 mg / 10 mg, 10 mg / 20 mg, 10 mg / 40 mg, 10 mg / 80 mg potahované tablety (Jedna tableta obsahuje ezetimibum 10 mg a atorvastatinum 10, 20, 40 nebo 80 mg).Indikace: Prevence kardiovaskulárních příhod – přípravek Zoletorv je indikován ke snížení rizika kardiovaskulárních příhod u pacientů s ischemickou chorobou srdeční (ICHS) a s anamnézou akutního koronárního syndromu (AKS), bez ohledu na to, zda předtím byli léčeni statinem. Hypercholesterolémie – jako přídatná terapie k dietě u pacientů s primární hypercholesterolémií nebo smíšenou hyperlipidémií, kde je vhodné použití kombinovaného přípravku: u pacientů, kteří nejsou samotným statinem dostatečně kontrolováni a u pacientů, kteří se již léčí statinem a ezetimibem. Dále jako přídatná terapie k dietě u homozygotní familiární hypercholesterolémie (HoFH). Dávkování a způsob podání: Tablety se podávají jednou denně perorálně, kdykoliv během dne, s jídlem nebo bez něj. Hypercholesterolémie a/nebo ischemická choroba srdeční (s AKS v anamnéze) – 10/10 mg/den až 10/80 mg/den. Obvyklá dávka je 10/10 mg jednou denně. Dávku přípravku Zoletorv je nutno individuálně upravit. Úprava dávky, pokud je zapotřebí, se musí provádět s odstupem minimálně 4 týdnů. Homozygotní familiární hypercholesterolémie – dávka přípravku Zoletorv je 10/10 až 10/80 mg denně. Současné podávání s jinými léčivými přípravky: Zoletorv je nutno podávat ≥ 2 hodiny před nebo ≥ 4 hodiny po podání sekvestrantu žlučových kyselin. U starších pacientů není nutno dávku upravovat. Bezpečnost a účinnost přípravku Zoletorv u dětí nebyla stanovena. Přípravek Zoletorv se u pacientů s poruchou funkce jater musí podávat opatrně. U pacientů s poruchou funkce ledvin není nutno dávku upravovat. Kontraindikace: Hypersenzitivita na léčivou látku(y) nebo na kteroukoli pomocnou látku. Těhotenství a kojení. Aktivní onemocnění jater nebo nevysvětlené přetrvávající zvýšení sérových transamináz přesahující 3násobek horního limitu normálu. Přípravek Zoletorv je kontraindikován u žen ve fertilním věku, pokud nepoužívají účinnou antikoncepci. Zvláštní upozornění a opatření pro použití: Myopatie/rhabdomyolýza: V rámci zkušeností s ezetimibem po jeho uvedení na trh byly hlášeny případy myopatie a rhabdomyolýzy. Většina pacientů, u nichž došlo k rozvoji rhabdomyolýzy, užívala statin současně s ezetimibem. U pacientů s predispozicí k rhabdomyolýze je nutno předepisovat přípravek Zoletorv opatrně. Všechny pacienty, u nichž se zahajuje léčba přípravkem Zoletorv nebo se dávka zvyšuje, je nutno poučit o riziku myopatie a upozornit je na nutnost okamžitě ohlásit jakoukoli nevysvětlenou svalovou bolest nebo slabost. Pokud jsou koncentrace CK zvýšeny nad 5násobek ULN, nelze léčbu zahájit. Pokud jsou svalové příznaky závažné a způsobují každodenní dyskomfort, i když jsou hladiny CK zvýšeny ≤ 5násobek ULN, je nutno zvážit vysazení léčby. Přípravek Zoletorv se musí vysadit, pokud dojde ke klinicky významnému zvýšení hladin CK (> 10násobek horního limitu normálu) nebo pokud je diagnostikována rhabdomyolýza nebo je na ni podezření. Jaterní enzymy: v kontrolovaných studiích souběžného podávání u pacientů léčených ezetimibem a atorvastatinem byla pozorována po sobě jdoucí zvýšení transamináz. Testy jaterních funkcí je nutno provést před zahájením léčby a poté je nutno je provádět pravidelně. Pokud zvýšení transamináz o více než 3násobek horní hranice normálu přetrvává, doporučuje se snížení dávky nebo vysazení přípravku Zoletorv. U pacientů se středně závažnou nebo závažnou jaterní nedostatečností se přípravek Zoletorv nedoporučuje. U pacientů s předchozí hemoragickou cévní mozkovou příhodou nebo lakunárním infarktem je poměr rizik a přínosů atorvastatinu v dávce 80 mg nejistý, přičemž potenciální riziko hemoragické cévní mozkové příhody je nutno před zahájením léčby pečlivě uvážit. V případě podezření, že se u pacienta vyvinula intersticiální plicní nemoc, musí být léčba statinem vysazena. Interakce s jinými léčivými přípravky a jiné formy interakce: Současné podávání přípravku Zoletorv a fi brátů se nedoporučuje. Při zahajování léčby přípravkem Zoletorv u pacientů léčených cyklosporinem je nutno postupovat opatrně a během léčby je nutno sledovat koncentrace cyklosporinu. V případech, kdy se přípravek Zoletorv přidá k warfarinu, jinému kumarinovému antikoagulanciu nebo fl uindionu, je nutno sledovat INR. Atorvastatin se nesmí podávat současně se systémovou léčbou kyselinou fusidovou nebo během 7 dnů po ukončení léčby kyselinou fusidovou. Současné podávání s léčivými přípravky, které mohou zvyšovat plazmatické koncentrace atorvastatinu, jako jsou silné inhibitory CYP3A4 nebo transportních proteinů, může zvyšovat riziko rhabdomyolýzy. Riziko myopatie může být zvýšeno při současném podávání gemfi brozilu a dalších derivátů kyseliny fi brové, bocepreviru, erythromycinu, niacinu, telapreviru nebo kombinace tipranavir/ritonavir. Dále viz úplné znění SPC. Nežádoucí účinky: Jako časté byly hlášeny průjem a myalgie. Pro úplnou informaci se seznamte s plným zněním SPC. Zvláštní opatření pro uchovávání: Uchovávejte v původním obalu, aby byl přípravek chráněn před kyslíkem. Druh obalu a velikost balení: Zoletorv 10 mg / 10 mg, 10 mg / 20 mg, 10 mg / 40 mg a 10 mg / 80 mg. Balení po 10, 30, 90 a 100 potahovaných tabletách v dusíkem profouknutých Al/Al blistrech (dutina z oPA-Al-PVC s víčkem z Al). Balení po 30x 1 a 45x 1 potahovaných tabletách v jednodávkových dusíkem profouknutých Al/Al blistrech (dutina z oPA-Al-PVC s víčkem z Al). Na trhu nemusí být všechny velikosti balení. Držitel rozhodnutí o registraci: Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Velká Británie. Registrační čísla: 31/403–406/14-C. Poslední revize textu: 12. 4. 2016. Dříve než přípravek předepíšete, seznamte se, prosím, s úplným souhrnem údajů o přípravku. Tento přípravek je vázán na lékařský předpis a je částečně hrazen z prostředkůveřejného zdravotního pojištění. POUZE PRO ODBORNOU VEŘEJNOST.

© Copyright Merck Sharp & Dohme s.r.o., 2016. Všechna práva vyhrazena.Merck Sharp & Dohme s.r.o., Evropská 2588/33a, 160 00 Praha 6, Česká republikaTel.: +420 233 010 111, e-mail: [email protected], www.msd.cz 08-2017-CARD-1193660-0000

1




NOTES




PARTNERSThe organizing committee would like to thank conference partners

for their strong support!

Gold Partner

Silver Partners

Partner

CONFERENCE SECRETARIATGUARANT InternationalNa Pankráci 17140 21 Prague 4Czech RepublicPhone: +420 284 001 444Fax: +420 284 001 448E-mail: [email protected]

WWW.PEDIM2016.ORG

Documents

2 Prague European Days of Internal Medicinefiles.test-pedim.webnode.cz/200000398-593275a2d8/... · Hotel Diplomat, Prague, Czech Republic 4 2 Prague European 5 Days of Internal Medicine